Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eagle-BDM vs Teva-BDM Bioequivalence in Cancer Patients
NCT02162888Phase 1Completed
- Sponsor
- Eagle Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bendamustine in cancer (3 arms), sponsored by Eagle Pharmaceuticals. Primary endpoint: Area Under the Concentration-Time Curve at 65 days. Started Nov 2013; status: completed.
02
Drugs
bendamustine
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02162888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162888.